Screener
Corvus Pharmaceuticals CRVS Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Corvus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-057100
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Research and development | $11,175 | $7,453 |
| General and administrative | 3,702 | 2,469 |
| Total operating expenses | 14,877 | 9,922 |
| Loss from operations | (14,877) | (9,922) |
| Interest income and other expense, net | 1,784 | 525 |
| Change in fair value of warrant liability | — | 25,129 |
| Loss before equity method investment | (13,093) | 15,732 |
| Loss from equity method investment | (599) | (539) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Corvus Pharmaceuticals's operating income?
- Corvus Pharmaceuticals (CRVS) reported operating income of -$14.88M in Q1 2026.
- How has Corvus Pharmaceuticals's operating income changed year-over-year?
- Corvus Pharmaceuticals's operating income decreased by 49.9% year-over-year, from -$9.92M to -$14.88M.
- What is the long-term trend for Corvus Pharmaceuticals's operating income?
- Over 4 years (2021 to 2025), Corvus Pharmaceuticals's operating income has grown at a 2.7% compound annual growth rate (CAGR), from -$38.63M to -$42.97M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Corvus Pharmaceuticals's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude